BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS (PRNewswire) - Apr 10, 2024 - P3 | N=196 | NCT03280056 | Sponsor: Brainstorm-Cell Therapeutics | "BrainStorm Cell Therapeutics Inc...announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve....The study analyzed forty-five biomarkers and identified three that are predictive of clinical outcomes in debamestrocel-treated participants, including neurofilaments light (NfL), LAP/TGFb1 and Galcetin-1. Treatment with debamestrocel led to significant changes in 64% of the forty-five analyzed biomarkers, spanning various pathways involved in ALS pathology. These changes included increases in anti-inflammatory and neuroprotective markers suggesting a potential ability to reduce inflammation and protect neurons, and decreases in inflammatory and neurodegenerative markers indicating a possible reduction in disease activity and nerve cell damage."
P3 data • Amyotrophic Lateral Sclerosis • CNS Disorders
|